Literature DB >> 7166177

Impairment of hepatic drug metabolism in patients with acute viral hepatitis.

A P Narang, D V Datta, N Nath, V S Mathur.   

Abstract

Hepatic drug metabolism in patients with acute viral hepatitis was investigated under different conditions: pregnancy, postpartum, non-pregnancy, and among males. Liver function tests were altered in all of these conditions. The relationship between in vivo and in vitro drug metabolism was studied in twenty-two patients using diagnostic liver needle biopsies by comparing the drug metabolising enzymes (aminopyrine-N-demethylase and bilirubin-UDP-glucuronyl transferase) in these biopsies with the elimination kinetics of antipyrine. Drug clearance tests were repeated in the patients who had recovered. All patients gave altered liver function tests results. Antipyrine half-life was significantly higher in females as compared to males. Among females, it was maximum in the pregnant group. Activities of drug metabolising enzymes were found to be significantly lower in liver biopsy material. The half-life of antipyrine showed a significant correlation with drug metabolising enzymes. After recovery patients showed a normal antipyrine half-life.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7166177     DOI: 10.1007/BF03189627

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  20 in total

1.  The estimation of antipyrine in biological materials.

Authors:  B B BRODIE; J AXELROD
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

Review 2.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Effects of pregnancy on the metabolism of drugs in the rat and rabbit.

Authors:  M G Neale; D V Parke
Journal:  Biochem Pharmacol       Date:  1973-06-15       Impact factor: 5.858

4.  Determination of bilirubin UDP-glucuronyl transferase activity in needle-biopsy specimens of human liver.

Authors:  M Black; B H Billing; K P Heirwegh
Journal:  Clin Chim Acta       Date:  1970-07       Impact factor: 3.786

5.  Comparison of in vivo and in vitro drug metabolism in experimental hepatic injury in the rat.

Authors:  R A Willson; F E Hart; J T Hew
Journal:  Gastroenterology       Date:  1979-04       Impact factor: 22.682

6.  Determination of drug metabolizing enzymes in needle biopsies of human liver.

Authors:  B Schoene; R A Fleischmann; H Remmer; H F von Oldershausen
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

7.  Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.

Authors:  M Homeida; C J Roberts; M Halliwell; A E Read; R A Branch
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

8.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

9.  Altered elimination of antipyrine in patients with acute viral hepatitis.

Authors:  D A Burnett; A J Barak; D J Tuma; M F Sorrell
Journal:  Gut       Date:  1976-05       Impact factor: 23.059

10.  Metabolism of amylobarbitone in patients with chronic liver disease.

Authors:  G E Mawer; N E Miller; L A Turnberg
Journal:  Br J Pharmacol       Date:  1972-03       Impact factor: 8.739

View more
  3 in total

Review 1.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  Reduction of paracetamol and aspirin metabolism during viral hepatitis.

Authors:  C Jorup-Rönström; B Beermann; E Wåhlin-Boll; A Melander; S Britton
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

3.  Single-dose kinetics of primidone in acute viral hepatitis.

Authors:  F Pisani; E Perucca; G Primerano; A A D'Agostino; R M Petrelli; A Fazio; G Oteri; R Di Perri
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.